Medically Integrated Dispensing in Oncology: Benefits & Challenges
The landscape of oncology care is evolving, with a growing emphasis on integrated approaches to treatment. A key component of this shift is medically integrated dispensing (MID), a model where prescribing, dispensing, and monitoring of medications occur within a single healthcare system. Katherine Tobon, PharmD, BCOP, of Moffitt Cancer Center, recently defined this approach and discussed its implementation and implications during a panel at the Institute for Value-Based Medicine® event in Tampa, Florida.
Understanding Medically Integrated Dispensing
What is MID?
Medically integrated dispensing is a care model that consolidates the prescribing, dispensing, and monitoring of medications within one healthcare system, rather than relying on external pharmacies. This is achieved through an internal specialty pharmacy, a dedicated team, and a clinical team focused on patient follow-up.
How Does it Work in Oncology?
Implementing MID involves establishing an internal specialty pharmacy and a collaborative team. This allows for in-house monitoring and dispensing, ultimately aiming to improve patient outcomes.
Benefits and Drawbacks of the Model
MID offers several potential advantages for both patients and providers. Faster treatment initiation and improved safety and monitoring are key benefits, as all information is centralized within a single electronic medical record (EMR). This streamlined approach is particularly valuable for patients undergoing complex treatment regimens.
The model also supports value-based and risk-based payment models, aligning incentives towards positive patient outcomes. However, MID is not without its challenges. Establishing a successful program requires a robust team of advanced clinical practitioners, clinical pharmacists, and specialty pharmacy personnel.
Potential limitations also include payer model restrictions, which can vary depending on insurance coverage. Access to new specialty medications may also be limited, and the initial startup costs and the need for highly trained professionals can be significant.
Looking Ahead
As oncology care continues to evolve, MID could become increasingly prevalent. However, its widespread adoption may depend on addressing the existing limitations, such as securing favorable payer agreements and ensuring access to necessary resources. Further advocacy and reform may be needed to sustain equitable, patient-centered cancer care. A possible next step could involve increased collaboration between oncology practices, pharmacies, and payers to optimize reimbursement models and streamline access to medications.
Frequently Asked Questions
What is the primary goal of medically integrated dispensing?
The primary goal is to improve patient outcomes by consolidating the prescribing, dispensing, and monitoring of medications within a single healthcare system.
What are some of the benefits for patients?
Patients may experience faster treatment initiation, improved safety and monitoring, and a better overall experience by working with a coordinated team within one institution.
What are some of the challenges associated with implementing MID?
Challenges include the need for a robust team of trained professionals, potential limitations in payer models, and higher startup costs.
As healthcare systems explore innovative ways to deliver cancer care, will integrated approaches like medically integrated dispensing become the standard of care?